Clinical trial
An International, Multicenter, Open-label, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of GenSci145, as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
NCT07407504 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International, Multicenter, Open-label, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of GenSci145, as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 1, 2026
- Completion date
- February 21, 2029
- Enrollment
- 186 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced or metastatic solid tumors with pik3ca-mutated